BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

11233

530239

SUVEN

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

SUVEN LIFE SCIENCES LTD performance

Today’s low

Today’s high

₹ 126.25 ₹ 131.83
₹ 127.50

52 week low

52 week high

₹ 82.95 ₹ 169.30
₹ 127.50

Open Price

₹ 130.87

Prev. Close

₹ 130.95

Volume (Shares)

223782.00

Total traded value

₹ 285.32

Upper Circuit

₹ 157.14

Lower Circuit

₹ 104.76

info

SUVEN LIFE SCIENCES LTD Share Price Update

As of the latest trading session, SUVEN LIFE SCIENCES LTD share price is currently at ₹ 127.5, which is down by ₹ -3.44 from its previous closing. Today, the stock has fluctuated between ₹ 126.25 and ₹ 131.83. Over the past year, SUVEN LIFE SCIENCES LTD has achieved a return of 17.60 %. In the last month alone, the return has been 7.30 %. Read More...

SUVEN LIFE SCIENCES LTD fundamentals


  • Market cap (Cr)

    2,780.44

  • P/E Ratio (TTM)

    -79.22

  • Beta

    1.18

  • Book Value / share

    37.92

  • Return on equity

    -2.36%

  • EPS (TTM)

    0.00

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    -13.27

info icon alternate text
  • Market cap (Cr)

    2,772.80

  • P/E Ratio (TTM)

    -79.22

  • Beta

    1.03

  • Book Value / share

    37.92

  • Return on equity

    -2.36%

  • EPS (TTM)

    0.00

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    -13.27

info icon alternate text

SUVEN LIFE SCIENCES LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 1.61
Operating Expense 16.45
Net Profit -13.27
Net Profit Margin (%) -824.22
Earnings Per Share (EPS) -0.61
EBITDA -11.73
Effective Tax Rate (%) 0.00
Particulars SEP 2024 (Values in Cr)
Revenue 2.57
Operating Expense 17.68
Net Profit -11.07
Net Profit Margin (%) -430.73
Earnings Per Share (EPS) -0.51
EBITDA -9.59
Effective Tax Rate (%) 0.00
Particulars JUN 2024 (Values in Cr)
Revenue 1.01
Operating Expense 12.60
Net Profit -7.67
Net Profit Margin (%) -759.40
Earnings Per Share (EPS) -0.35
EBITDA -6.16
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 2.39
Operating Expense 10.79
Net Profit -3.12
Net Profit Margin (%) -130.54
Earnings Per Share (EPS) -0.14
EBITDA -2.59
Effective Tax Rate (%) 24.21
Particulars DEC 2023 (Values in Cr)
Revenue 2.45
Operating Expense 13.29
Net Profit -4.77
Net Profit Margin (%) -194.69
Earnings Per Share (EPS) -0.22
EBITDA -3.12
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 11.69
Operating Expense 49.29
Net Profit -8.01
Net Profit Margin (%) -68.52
Earnings Per Share (EPS) -0.37
EBITDA -2.34
Effective Tax Rate (%) 11.09
Particulars MAR 2023 (Values in Cr)
Revenue 13.54
Operating Expense 48.12
Net Profit -20.13
Net Profit Margin (%) -148.67
Earnings Per Share (EPS) -1.13
EBITDA -13.30
Effective Tax Rate (%) 0.00
Particulars MAR 2022 (Values in Cr)
Revenue 11.84
Operating Expense 53.41
Net Profit -36.25
Net Profit Margin (%) -306.16
Earnings Per Share (EPS) -2.69
EBITDA -31.33
Effective Tax Rate (%) 0.00
Particulars MAR 2021 (Values in Cr)
Revenue 13.48
Operating Expense 49.19
Net Profit -22.63
Net Profit Margin (%) -167.87
Earnings Per Share (EPS) -1.78
EBITDA -22.78
Effective Tax Rate (%) 19.03
Particulars MAR 2020 (Values in Cr)
Revenue 14.41
Operating Expense 54.39
Net Profit -13.75
Net Profit Margin (%) -95.41
Earnings Per Share (EPS) -1.08
EBITDA -21.28
Effective Tax Rate (%) 46.95
Particulars MAR 2024 (Values in Cr)
Book Value / Share 12.38
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -951.97
Particulars MAR 2023 (Values in Cr)
Book Value / Share 17.21
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.01
EBITDA Margin -822.08
Particulars MAR 2022 (Values in Cr)
Book Value / Share 6.61
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.04
EBITDA Margin -987.58
Particulars MAR 2021 (Values in Cr)
Book Value / Share 5.58
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.04
EBITDA Margin -535.53
Particulars MAR 2020 (Values in Cr)
Book Value / Share 11.26
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.02
EBITDA Margin -705.62
Particulars MAR 2024 (Values in Cr)
Book Value / Share 38.77
ROE % -2.36
ROCE % -2.44
Total Debt to Total Equity 0.00
EBITDA Margin -122.16
Particulars MAR 2023 (Values in Cr)
Book Value / Share 39.14
ROE % -4.20
ROCE % -4.11
Total Debt to Total Equity 0.00
EBITDA Margin -154.87
Particulars MAR 2022 (Values in Cr)
Book Value / Share 32.74
ROE % -9.17
ROCE % -8.90
Total Debt to Total Equity 0.01
EBITDA Margin -297.38
Particulars MAR 2021 (Values in Cr)
Book Value / Share 28.66
ROE % -5.73
ROCE % -6.73
Total Debt to Total Equity 0.01
EBITDA Margin -168.40
Particulars MAR 2020 (Values in Cr)
Book Value / Share 30.46
ROE % -3.48
ROCE % -6.33
Total Debt to Total Equity 0.01
EBITDA Margin -147.33
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 163.97
Total Assets 284.90
Total Liabilities 284.90
Total Equity 270.04
Share Outstanding 218073717
Price to Book Ratio 2.57
Return on Assets (%) -36.88
Return on Capital (%) -38.91
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 184.28
Total Assets 388.91
Total Liabilities 388.91
Total Equity 375.31
Share Outstanding 218073717
Price to Book Ratio 1.24
Return on Assets (%) -30.41
Return on Capital (%) -31.51
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 5.52
Total Assets 108.03
Total Liabilities 108.03
Total Equity 96.14
Share Outstanding 145382478
Price to Book Ratio 2.83
Return on Assets (%) -112.92
Return on Capital (%) -126.25
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 46.64
Total Assets 128.41
Total Liabilities 128.41
Total Equity 108.00
Share Outstanding 127282478
Price to Book Ratio 2.46
Return on Assets (%) -56.18
Return on Capital (%) -65.99
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 15.09
Total Assets 181.93
Total Liabilities 181.93
Total Equity 143.34
Share Outstanding 127282478
Price to Book Ratio 0.70
Return on Assets (%) -51.78
Return on Capital (%) -65.23
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 153.44
Total Assets 851.48
Total Liabilities 851.48
Total Equity 845.37
Share Outstanding 218073717
Price to Book Ratio 2.57
Return on Assets (%) -0.94
Return on Capital (%) -0.95
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 173.95
Total Assets 860.44
Total Liabilities 860.44
Total Equity 853.44
Share Outstanding 218073717
Price to Book Ratio 1.24
Return on Assets (%) -2.33
Return on Capital (%) -2.36
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 3.14
Total Assets 486.35
Total Liabilities 486.35
Total Equity 475.97
Share Outstanding 145382478
Price to Book Ratio 2.83
Return on Assets (%) -7.45
Return on Capital (%) -7.61
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 38.59
Total Assets 415.38
Total Liabilities 415.38
Total Equity 401.65
Share Outstanding 127282478
Price to Book Ratio 2.46
Return on Assets (%) -5.44
Return on Capital (%) -5.62
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1.12
Total Assets 409.75
Total Liabilities 409.75
Total Equity 387.67
Share Outstanding 127282478
Price to Book Ratio 0.70
Return on Assets (%) -3.35
Return on Capital (%) -3.54
Particulars MAR 2024 (Values in Cr)
Net Income -106.07
Cash from Operations -121.64
Cash from Investing 94.43
Cash from Financing -1.05
Net change in Cash -22.08
Free Cash Flow -121.64
Particulars MAR 2023 (Values in Cr)
Net Income -118.26
Cash from Operations -114.87
Cash from Investing -247.81
Cash from Financing 395.53
Net change in Cash 31.74
Free Cash Flow -111.98
Particulars MAR 2022 (Values in Cr)
Net Income -121.99
Cash from Operations -127.01
Cash from Investing -22.22
Cash from Financing 145.69
Net change in Cash -4.07
Free Cash Flow -107.24
Particulars MAR 2021 (Values in Cr)
Net Income -77.47
Cash from Operations -94.87
Cash from Investing 55.84
Cash from Financing 34.85
Net change in Cash -5.32
Free Cash Flow -88.57
Particulars MAR 2020 (Values in Cr)
Net Income -106.40
Cash from Operations -131.79
Cash from Investing 146.21
Cash from Financing 2.80
Net change in Cash 14.44
Free Cash Flow -129.40
Particulars MAR 2024 (Values in Cr)
Net Income -9.01
Cash from Operations -26.73
Cash from Investing -0.67
Cash from Financing -1.05
Net change in Cash -22.29
Free Cash Flow -26.73
Particulars MAR 2023 (Values in Cr)
Net Income -20.12
Cash from Operations -21.81
Cash from Investing -348.82
Cash from Financing 395.53
Net change in Cash 23.79
Free Cash Flow -18.92
Particulars MAR 2022 (Values in Cr)
Net Income -36.24
Cash from Operations -36.10
Cash from Investing -107.45
Cash from Financing 145.69
Net change in Cash 1.60
Free Cash Flow -16.33
Particulars MAR 2021 (Values in Cr)
Net Income -27.95
Cash from Operations -35.53
Cash from Investing 2.41
Cash from Financing 34.85
Net change in Cash 0.58
Free Cash Flow -29.23
Particulars MAR 2020 (Values in Cr)
Net Income -25.93
Cash from Operations -42.36
Cash from Investing 42.03
Cash from Financing 3.81
Net change in Cash 0.69
Free Cash Flow -39.98
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 6992.60 76.74 13.41 100542.86 5690.80 / 7545.10
FORTIS MALAR HOSPITALS LIMITED 78.74 192.05 4.94 147.57 51.01 / 98.70
SHREE PACETRONIX LTD. 71.00 14.79 1.90 25.56 61.11 / 268.50
TRANSGENE BIOTEK LTD. 3.75 0.00 2.62 28.41 3.22 / 10.84
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 6992.60 83.66 12.27 100542.86 5690.80 / 7545.10
Surlux Diagnostic Ltd 1.40 0.84 0.13 0.49 0.00 / 0.00
CHENNAI MEENAKSHI MULTISPECIAL 31.25 0.00 -16.74 23.34 28.34 / 59.90
KOVAI MEDICAL CENTER & HOSPITA 5584.95 29.60 6.27 6109.94 3750.00 / 6400.00

SUVEN LIFE SCIENCES LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
127.50 -2.63 redarrow
red-green-graph indicator
8 Bearish
8 Bullish
  • 5 Days 130.90
  • 26 Days 126.80
  • 10 Days 130.30
  • 50 Days 125.10
  • 12 Days 129.70
  • 100 Days 125.60
  • 20 Days 127.80
  • 200 Days 123.60
132.17 PIVOT

First Support

128.78

First Resistance

134.35

Second Support

126.60

Second Resistance

137.74

Third Support

123.21

Third Resistance

139.92

RSI

54.71

ADX

32.79

MACD

3.45

Williams % R

-50.21

Commodity Channel Index (CCI)

67.57

Date

2025-04-29

Week

236418.00

Same Day

161795.00

Month

210863.00

1 Year

1.18

3 Year

1.03

Over 1 Month

7.30%

down

Over 1 Year

17.60%

down

Over 3 Months

14.80%

down

Over 3 Years

17.64%

down

Over 6 Months

11.07%

down

Over 5 Years

26.54%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

SUVEN LIFE SCIENCES LTD shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
29.47%
Promoter Holdings
70.26%
FII
0.25%
DII
0.0%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Jasti Property And Equity Holdings Private Limited (initscapacityassoletrusteeofjastifamilytrust) 1.516975E8 (69.56%) Shareholding of Promoter and Promoter Group
Sudharani Jasti 1528535.0 (0.7%) Shareholding of Promoter and Promoter Group
Venkateswarlu Jasti 2201.0 (0.0%) Shareholding of Promoter and Promoter Group
Sirisha Jasti 1000.0 (0.0%) Shareholding of Promoter and Promoter Group
Kalyani Jasti 1000.0 (0.0%) Shareholding of Promoter and Promoter Group
Madhavi Jasti 1000.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

SUVEN LIFE SCIENCES LTD corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
14 Feb 2019 1.5 Interim 15 Feb 2019 Equity shares
06 Feb 2018 1.5 Interim 07 Feb 2018 Equity shares
08 Feb 2017 1.0 Interim 09 Feb 2017 Equity shares
14 Mar 2016 1.0 Interim 15 Mar 2016 Equity shares
14 Mar 2016 1.0 Special 15 Mar 2016 Equity shares
23 Jul 2015 0.6 Final 25 Jul 2015 Equity shares
24 Jul 2014 0.5 Final 26 Jul 2014 Equity shares
24 Jul 2014 2.0 Special 26 Jul 2014 Equity shares
01 Aug 2013 0.3 Final 05 Aug 2013 Equity shares
17 Sep 2012 0.3 Final 19 Sep 2012 Equity shares
01 Aug 2011 0.25 Final 03 Aug 2011 Equity shares
19 Jul 2010 0.25 Final 21 Jul 2010 Equity shares
14 Sep 2009 0.25 Final 16 Sep 2009 Equity shares
11 Sep 2008 0.25 Final 13 Sep 2008 Equity shares
21 Sep 2007 0.25 Final 25 Sep 2007 Equity shares
25 Sep 2006 0.0 Final 27 Sep 2006 Equity shares
05 Sep 2005 0.0 Final 08 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
02 Apr 2007 23 Mar 2007 1:1
Ex-Date Old FV NEW FV Record Date
23 Mar 2007 2.0 1.0 02 Apr 2007
15 Jan 2004 10.0 2.0 23 Jan 2004
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
14 Feb 2019 1.5 Interim 15 Feb 2019 Equity shares
06 Feb 2018 1.5 Interim 07 Feb 2018 Equity shares
08 Feb 2017 1.0 Interim 09 Feb 2017 Equity shares
14 Mar 2016 1.0 Interim 15 Mar 2016 Equity shares
14 Mar 2016 1.0 Special 15 Mar 2016 Equity shares
23 Jul 2015 0.6 Final 25 Jul 2015 Equity shares
24 Jul 2014 0.5 Final 26 Jul 2014 Equity shares
24 Jul 2014 2.0 Special 26 Jul 2014 Equity shares
01 Aug 2013 0.3 Final 05 Aug 2013 Equity shares
17 Sep 2012 0.3 Final 19 Sep 2012 Equity shares
01 Aug 2011 0.25 Final 03 Aug 2011 Equity shares
19 Jul 2010 0.25 Final 21 Jul 2010 Equity shares
14 Sep 2009 0.25 Final 16 Sep 2009 Equity shares
11 Sep 2008 0.25 Final 13 Sep 2008 Equity shares
21 Sep 2007 0.25 Final 25 Sep 2007 Equity shares
25 Sep 2006 0.0 Final 27 Sep 2006 Equity shares
05 Sep 2005 0.0 Final 08 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
02 Apr 2007 23 Mar 2007 1:1
Ex-Date Old FV NEW FV Record Date
23 Mar 2007 2.0 1.0 02 Apr 2007
15 Jan 2004 10.0 2.0 23 Jan 2004

SUVEN LIFE SCIENCES LTD Share Price

Suven Life Sciences Limited (Formerly known as Suven Pharmaceuticals Ltd) was incorporated in March, 1989. The Company changed its name from Suven Pharmaceuticals Limited to Suven Life Sciences Limited in September, 2003. Promoted by Sudharani Jasti and Venkateswarlu Jasti, the Company began operations in 1989 as specialty chemicals provider.

The Company is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. Suven has a wholly owned subsidiary, Suven Neurosciences, Inc., USA, focused on clinical development activities of Suven molecules from phase 2, Proof-of-Concept (POC) studies.

The Company is in the business of Contract Research And Manufacturing Services (CRAMS), catering to the needs of global life science industry and fine chemical majors. Suven's CRAMS provide innovative process research and development, supplies to clinical trials, rapid response pilot scale manufacture, dedicated commercial manufacturing on an exclusive basis. The services include Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations. Suven Life Sciences has graduated from contract research to Collaborative Research transitioning from project-based transactions into relationship-based business.

In March 1995, SPL came out with a public issue of 9.8 lac equity shares at a premium of Rs 40 aggregating Rs 4.9 cr to part-finance the company's project for the manufacture of bulk drugs and drug intermediates and meet long-term working capital requirements totalling to Rs 6.43 cr.

During 1999-2000, the company acquired a small pilot plant in Jeedimetla Industrial Estate, Hyderabad.

During 2000-01, the company has registered a most remarkable record. The total sales of the company during 2000-01 have registered a growth of 71% over the previous year. The Profit After Tax (PAT) has also registered a growth of 325% over the previous year.

During the financial year ended 31 March 2014, Suven's Drug discovery portfolio has expanded into several new therapeutic areas such as Major Depressive Disorder (MDD), Obesity and Pain through Neuronal Nicotinic Receptor modulators. In addition, D-4010 and G3031 are undergoing regulatory toxicological studies in preparation for them being moving into Phase 1 clinical trial during 2014-15.

During the year 2014, Suven has made significant inroads into drug discovery with a specialization on CNS-based programmes targeting unmet medical needs. The Company enjoys a unique position in the India (and Asia) as one of the prominent company with technologies under central nervous system (CNS). It has funded drug discovery for nine years resulting in a robust pipeline of 14 molecules at various stages of development. Suven's discovery assets address niche therapeutic areas like cognition, depression, obesity and pain management.

In FY14, the Company filed one ANDA with the USFDA authorities for Malathion lotion, a head-lice product with sales potential estimated at US$35 million. In 2013-14, it granted the exclusive license to Taro Pharmaceuticals to market the product in the US, Canada and Mexico, which is expected to generate revenues and royalty in 2014-15.

During FY2015, Suven's lead clinical candidate SUVN-502 has successfully completed Phase 1b clinical trial thus paving the way for the co-pound to move into Proof of Concept (PoC) Phase 2a study. In addition to above compounds, SUVN D-4010 is in its final stages of completing regulatory toxicological studies which will enable it to move into Phase 1 clinical trial in USA.

During the FY2015, the Company has issued and allotted 104,53,690 equity shares of Re 1/- each at a premium of Rs 190.32 per share by way of QIP Issue in accordance with the SEBI ICDR guidelines.

During FY15, the Company's main focus stayed on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.

During FY15, the Company added two new clients to its CRAMS business. It commenced operations at its Vishakhapatnam unit and shifted the manufacturing intermediates for a specialty chemical product to this unit. The shift not only optimized capacities at its CRAMS facilities but also made the CRAMS operations more efficient.

During FY2017, the company has spent Rs. 6973 lakhs on innovative R&D in CNS therapies accounting for 13% on sales. Its focus remained on discovering, developing and commercializing novel pharmaceutical products, which are first in class CNS therapies through use of GPCR targets.

During FY 2017, the Company has invested a sum of Rs 6501 lakhs in Suven Neurosciences Inc., a wholly owned subsidiary, for its business purpose.

In FY2018, the company has spent Rs 6,390 lakhs on innovative R&D in CNS therapies accounting for 10% on sales.

The Company invested a sum of Rs.13,636 lakhs in Suven Neurosciences, Inc., for its business purpose. The Company acquired entire share capital of Rs.1 lakh in Suven Pharmaceuticals Limited identified as Resulting Company for the purpose of Scheme of Arrangement (Demerger) and as of 31st March, 2019 no investments were made in newly formed Suven Pharma, Inc. in USA.

During the FY 2018-2019, Suven Pharmaceuticals Limited in India and Suven Pharma, Inc., in USA became the subsidiary companies.

In 2018-19, the Company completed the Clinical Trial (Phase II) of the lead molecule SUVN-502, Masupirdine. In 2019-20, the Contract Research and Manufacturing Services (CRAMS) Undertaking of the Company was demerged to its wholly owned subsidiary, Suven Pharmaceuticals Limited as a going concern through a Scheme of Arrangement effective from 1st October, 2018.

Parent organization Indian Private
NSE symbol SUVEN
Founded 1989
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Suven Life Sciences Ltd?

Answer Field

The share price of Suven Life Sciences Ltd for NSE is ₹ 127.5 and for BSE is ₹ 127.15.

What is the Market Cap of Suven Life Sciences Ltd?

Answer Field

The market cap of Suven Life Sciences Ltd for NSE is ₹ 27,80.44 Cr. and for BSE is ₹ 27,72.80 Cr. as of now.

What is the 52 Week High and Low of Suven Life Sciences Ltd?

Answer Field

The 52 Week High and Low of Suven Life Sciences Ltd for NSE is ₹ 169.30 and ₹ 82.95 and for BSE is ₹ 169.00 and ₹ 83.27.

How to Buy Suven Life Sciences Ltd share?

Answer Field

You can trade in Suven Life Sciences Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Suven Life Sciences Ltd?

Answer Field

The 1 year returns on the stock has been 15.43%.

What is the Current Share Price of Suven Life Sciences Ltd?

Answer Field

Suven Life Sciences Ltd share price is for NSE ₹ 127.5 & for BSE ₹ 127.15 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Suven Life Sciences Ltd Share?

Answer Field

The market cap of Suven Life Sciences Ltd for NSE ₹ 27,80.44 & for BSE ₹ 27,72.80 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Suven Life Sciences Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Suven Life Sciences Ltd share is -79.22.

What is the PB ratio of Suven Life Sciences Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Suven Life Sciences Ltd share is 37.92.

How to Buy Suven Life Sciences Ltd Share?

Answer Field

You can trade in Suven Life Sciences Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Suven Life Sciences Ltd Share on Bajaj Broking App?

Answer Field

To buy Suven Life Sciences Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Suven Life Sciences Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|